Stay updated on Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Sign up to get notified when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.

Latest updates to the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page
- Check6 days agoNo Change Detected
- Check14 days agoChange DetectedRevision: v3.4.2 was added. The government funding status notice and Revision: v3.4.1 were removed.SummaryDifference0.4%

- Check21 days agoChange DetectedAdded a government funding lapse notice and Clinical Center status guidance, and updated the site revision to v3.4.1 (replacing v3.4.0); to avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check28 days agoChange DetectedGlossary display has been added, and the label 'Last Update Submitted that Met QC Criteria' appears with updated capitalization. Footer text now shows 'No FEAR Act data' and 'Revision: v3.4.0', replacing the previous wording and version.SummaryDifference0.2%

- Check42 days agoChange DetectedMinor revision label updated from v3.3.3 to v3.3.4; no changes to study details, eligibility criteria, or user actions. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check63 days agoChange DetectedA new consolidated Locations section lists participating sites by state (Florida, Missouri, Oklahoma, Tennessee, Texas, Wisconsin) and the prior state-specific location subsections have been removed.SummaryDifference0.7%

- Check92 days agoChange DetectedRevision updated to v3.3.2. The previous revision v3.2.0 was removed.SummaryDifference0.1%

Stay in the know with updates to Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Esom/Rifampin Safety, PK and Alisertib QT Clinical Trial page.